Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Net Income (2016 - 2025)

Iradimed (IRMD) has disclosed Net Income for 13 consecutive years, with $5.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income rose 10.44% to $5.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $20.5 million, a 9.99% increase, with the full-year FY2024 number at $18.5 million, up 7.81% from a year prior.
  • Net Income was $5.6 million for Q3 2025 at Iradimed, down from $5.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $5.8 million in Q2 2025 to a low of $1.4 million in Q1 2021.
  • A 5-year average of $3.9 million and a median of $4.1 million in 2024 define the central range for Net Income.
  • Biggest YoY gain for Net Income was 279.2% in 2021; the steepest drop was 21.61% in 2021.
  • Iradimed's Net Income stood at $3.9 million in 2021, then fell by 3.97% to $3.7 million in 2022, then grew by 21.45% to $4.5 million in 2023, then decreased by 1.99% to $4.4 million in 2024, then grew by 25.34% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Net Income are $5.6 million (Q3 2025), $5.8 million (Q2 2025), and $4.7 million (Q1 2025).